Skip to content

Continuous and Wireless Vital Sign Monitoring in Patients at Home After Acute Medical Admission

Continuous and Wireless Vital Sign Monitoring in Patients at Home After Acute Medical Admission

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05536206
Acronym
WARD-HOME
Enrollment
30
Registered
2022-09-10
Start date
2022-12-01
Completion date
2023-07-30
Last updated
2023-09-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical Deterioration, Disease Attributes, Disease Progression, Vital Sign Monitoring

Brief summary

The current study aims to investigate the feasibility of transmitting continuous and wireless vital sign data in real time from patients home to the hospital in patients discharged after an acute medical hospitalization

Detailed description

The healthcare system is challenged by an aging patient population with chronic diseases, and acute admissions must be housed in hospitals with fewer beds and less staff resources. This increases the need for earlier discharge and for treatment shifted to the patients' own home. Furthermore, the transition from the hospital to the home setting is one of potential hazard, due to the lack of observation and intervention possibilities. This study aims to investigate the feasibility of wireless, continuous monitoring of patients in the days around discharge after an acute medical hospitalization, as well as occurrence of deviating vital signs i in the patients' own homes during the first days after discharge. Data will be transmitted continuously in real time from patient's homes to mobile applications for portable handheld devices such as healthcare personnel's smartphones.

Interventions

DEVICEWireless and continuously monitoring

Included patients are monitored with WARD equipment during the last part of hospitalization and the first days after discharge with data transmitted in real time to personnel at the hospital. Monitoring will last for a maximum of 72 hours.

Sponsors

Rigshospitalet, Denmark
CollaboratorOTHER
Technical University of Denmark
CollaboratorOTHER
Bispebjerg Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (≥18 years) Admitted with an acute medical disease and scheduled for discharge to their own homes within five days from inclusion.

Exclusion criteria

* Allergy to plaster, plastic, or silicone. * A pacemaker or Implantable Cardioverter Defibrillator (ICD) device. * If the patient was deemed not able to open the front door when visited by the investigator. * Inability to give informed consent.

Design outcomes

Primary

MeasureTime frame
Duration of data collection from the Lifetouch patchUp to 72 hours of monitoring

Secondary

MeasureTime frameDescription
Duration of complete peripheral saturation dataUp to 72 hours of monitoring
Duration of complete blood pressure dataUp to 72 hours of monitoring
Cummulated duration of desaturationUp to 72 hours of monitoringPeripheral saturation below 88% and 85%
Number of events with SpO2 < 85% in at least 5 consecutive minutesUp to 72 hours of monitoring
Number of deviating vital parameters in accordance to defined microeventsUp to 72 hours of monitoring
Number of events with SpO2 < 88% in at least 10 consecutive minutesUp to 72 hours of monitoring

Other

MeasureTime frame
Re-admission and cause of re-admission within 30-days30-days follow up
User experiences (patient and personnel)Within 72 hours of monitoring

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026